These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 363251)

  • 1. Variation of macrophage migration by a factor from regional lymph node cells of breast cancer patients.
    Fisher B; Golinger RC; Kelly M; Ruth D
    Cancer; 1978 Nov; 42(5):2097-100. PubMed ID: 363251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer metastasis and lymph node lymphocyte-macrophage interaction.
    Richters A
    J Surg Oncol; 1980; 13(3):227-30. PubMed ID: 7374157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of macrophage migration inhibitory factor in human breast cancer: association with nodal spread.
    Bando H; Matsumoto G; Bando M; Muta M; Ogawa T; Funata N; Nishihira J; Koike M; Toi M
    Jpn J Cancer Res; 2002 Apr; 93(4):389-96. PubMed ID: 11985788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphokines. I. Use of insoluble concanavalin A for the production of migration inhibitory factor in guinea pig lymphocyte cultures.
    Friedrich W; Lazary S; Geczy C; de Weck AL
    Int Arch Allergy Appl Immunol; 1975; 49(4):504-18. PubMed ID: 1099010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guinea pig macrophage agglutination factor is antigenically distinct from migration inhibition factor and immunoglobulin.
    Godfrey HP; Geczy CL
    J Immunol; 1978 Oct; 121(4):1428-31. PubMed ID: 359706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymph node-breast carcinoma interrelations in tissue culture.
    Gewant WC; Chasin L; Tilson MD; Rutledge C; Goldenberg IS
    Surg Gynecol Obstet; 1971 Dec; 133(6):959-62. PubMed ID: 5117393
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of the concentration of inducing agent on the output of lymphokines in the guinea pig.
    Ford WH; Ashworth LA; Inder S
    Eur J Immunol; 1976 Feb; 6(2):135-8. PubMed ID: 786697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune interferon. II. Different cellular site for the production of murine macrophage migration inhibitory factor and interferon.
    Neumann C; Sorg C
    Eur J Immunol; 1978 Aug; 8(8):582-9. PubMed ID: 359337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro responses of primed rabbit lymph node cells to myoglobin and its synthetic antigenic peptides: production of macrophage inhibitory factor and antibody to myoglobin.
    Stavitsky AB; Atassi MZ; Gooch GT; Pelley RP; Harold WW
    Immunochemistry; 1975 Dec; 12(12):959-65. PubMed ID: 767252
    [No Abstract]   [Full Text] [Related]  

  • 10. Production of leucocyte inhibitory factor (LIF) and macrophage inhibitory factor (MIF) by PHA-stimulated lymphocytes.
    Ruthlomnitzer ; Rabson AR; Koornhof HJ
    Clin Exp Immunol; 1975 Dec; 22(3):522-7. PubMed ID: 773578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variations in lymphokine generation by individual lymph nodes draining human malignant tumors.
    Wen DR; Hoon DS; Chang C; Cochran AJ
    Cancer Immunol Immunother; 1989; 30(5):277-82. PubMed ID: 2696592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrophage requirement for production of guinea pig migration inhibitory factor (MIF) in vitro.
    Nelson RD; Leu RW
    J Immunol; 1975 Feb; 114(2 Pt 1):606-9. PubMed ID: 47355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axillary lymph node cellular immune response to HER-2/neu peptides in patients with carcinoma of the breast.
    Kuerer HM; Peoples GE; Sahin AA; Murray JL; Singletary SE; Castilleja A; Hunt KK; Gershenson DM; Ioannides CG
    J Interferon Cytokine Res; 2002 May; 22(5):583-92. PubMed ID: 12060497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunologic competence of regional lymph nodes in patients with breast cancer.
    Ellis RJ; Wernick G; Zabriskie JB; Goldman LI
    Cancer; 1975 Mar; 35(3):655-9. PubMed ID: 1111934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of action of migration inhibitory factor (MIF). I. Evidence for a receptor for MIF present on the peritoneal macrophage but not on the alveolar macrophage.
    Leu RW; Eddleston AL; Hadden JW; Good RA
    J Exp Med; 1972 Sep; 136(3):589-603. PubMed ID: 4115133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma.
    Turner RR; Ollila DW; Krasne DL; Giuliano AE
    Ann Surg; 1997 Sep; 226(3):271-6; discussion 276-8. PubMed ID: 9339933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Staging of women with breast cancer after introduction of sentinel node guided axillary dissection.
    Tvedskov TF
    Dan Med J; 2012 Jul; 59(7):B4475. PubMed ID: 22759850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibody-defined phenotypes of regional lymph node and peripheral blood lymphocyte subpopulations in early breast cancer.
    Morton BA; Ramey WG; Paderon H; Miller RE
    Cancer Res; 1986 Apr; 46(4 Pt 2):2121-6. PubMed ID: 3081262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of non-sentinel lymph node metastasis in breast cancer patients.
    Goyal A; Douglas-Jones A; Newcombe RG; Mansel RE;
    Eur J Cancer; 2004 Jul; 40(11):1731-7. PubMed ID: 15251163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of macrophages to defective delayed-type hypersensitivity in B6/lpr mice.
    Okuyama H; Yamamoto K; Matsunaga T; Kobayashi S; Hashimoto Y
    Clin Exp Immunol; 1986 Dec; 66(3):599-605. PubMed ID: 3552337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.